Explore >> Select a destination
|
You are here 
|
www.mutualfundobserver.com | ||
| | | | |
blog.instavest.com
|
|
| | | | | "Hedge funds are for suckers," Bloomberg proclaimed in a headline in 2013. According to the article, one reason they're "for suckers" is they are expensive. The industry standard for the management of these funds is known as the "2 & 20" rule:... | Instavest Blog | Svbtle | |
| | | | |
yolken.net
|
|
| | | | | I recently had the opportunity to invest in a venture capital fund. In this post, I want to explain how these funds work and what I've learned from the experience so far. | |
| | | | |
www.insidermonkey.com
|
|
| | | | | Hedge funds returned 8.5% in 2017, 5.5% in 2016, -0.4% in 2015, 1.4% in 2014, 11.1% in 2013, and 4.8% in 2012. These are embarrassingly low compared to the S&P 500 ETF (SPY)'s 21.7% gain in 2017, 12% gain in 2016, 1.2% gain in 2015, 13.5% gain in 2014, 32.3% gain in 2013, and 16% gain in 2012. | |
| | | | |
masonq.com
|
|
| | | Colossal Biosciences, a leading biotech firm in the USA, has successfully raised $200 million in Serie C funding from TWG Global. This financial boost positions the company for significant advancements in its innovative projects, contributing to its mission within the biotechnology sector. | ||
